

FASENRA (BENRALIZUMAB) INJECTION ORDERS P: 877.365.5566 | F: 855.889.2946

PHI-REF-ORD-10114-V4

A Carelon Company

PATIENT	INFORMATION:	Fax completed form, insura	nce information, and clinic	cal documentation to 855.889.2946	
Patient Nam	ne:		DOB:	Phone:	
Patient Stat	us: □ New to Therapy	Continuing Therapy	Next Treatment Da	te:	
MEDICAL INFORMATION					
Diagnosis:	Imagnosis: Severe persistent asthma, uncomplicated (ICD-10 code: J45.50) Severe persistent asthma with acute exacerbation (ICD-10 code: J45.51) Other: (ICD-10 code:)				
Patient Weight: lbs. (required) Allergies:					

THERAPY ORDER

Fasenra:

□ Initial Dose: 30mg subcutaneously every 4 weeks for the first 3 doses followed by once every 8 weeks therafter x1 year

□ Maintenance Dose: 30mg subcutaneously every 8 weeks x1 year

Lab Orders:		Lab Frequency:	
Required labs to be drawn by:	□ Infusion Center	Referring Provider	
Other orders:			

	Ir services, you are authorizing Paragon	Healthcare, Inc. and its employees to serve		horization and	specialty pharmacy designated
		select the preferred site of care for the pa Signature:			Date:
Provider NPI:	Phone:	_ Signature: Date: Fax: Contact Person:			
□ Opt out of Paragon	selecting site of care (i	f checked, please list site	of care):		
PREFERRED LOC					
City:	State:	View our locat	ions here:		
		PARAGONHEALTHCARE.COM ed address and contains material that is c te, distribute, or copy this fax. Please notify this document in error.			





COMPREHENSIVE SUPPORT FOR FASENRA (BENRALIZUMAB) THERAPY

A Carelon Company

PATIENT INFORMATION:

Patient Name:	DOB:
REQUIRED DOCUMENTATION FOR REFERRAL PR	OCESSING & INSURANCE APPROVAL
Include <u>signed</u> and <u>completed</u> order (MD/prescr	iber to complete page 1)
Include patient demographic information and instant	surance information
Include patient's medication list	
Supporting clinical notes to include any past trie benefits, or contraindications to conventional the	• • •
 Please indicate any tried and failed therapies: Inhaled corticosteroids Long acting beta 2 agonist 	
Long acting muscarinic antagonist	
 Does the patient have a history of 2 exacerba systemic corticosteroids, hospitalization or a 12-month period? 	
Does the patient have an ACQ score consister consistently less than 120?	ntly greater than 1.5 or ACT score
Include labs and/or test results to support diagn	osis
□ Does patient have a baseline peripheral blood within the past 6 weeks? □ Yes □ No (att	•
EV1 score:	
□ Is the patient or caregiver <u>able</u> to administer Fas □ Yes □ No If no, please state reason:	
Other medical necessity:	

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance

PARAGONHEALTHCARE.COM